Develops early-stage small molecules and late-stage novel formulations for rheumatology, CNS, oncology and immunology, aiming to improve therapeutic index and overcome treatment barriers. Lead product VOLT01 is a reformulated zoledronic acid for knee osteoarthritis with improved safety and efficacy, no post-dosing symptoms, and potential as a disease-modifying osteoarthritis drug (DMARD).